Evidence map›Paper›PMID 34417356›Full record

ArticleBehavioural pharmacology2021

Nicotinic aspects of the discriminative stimulus effects of arecoline.

Gail Winger

Open access · greenAbstract read
In one paragraph

Article in Behavioural pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Gail WingerDepartment of Pharmacology, University of Texas Health, San Antonio, Texas, USA.
The University of Texas Health Science Center at San Antonio · US

Funding

Preclinical Identification of Better Antimuscarinic AntidepressantsR01MH107499 · NIMH · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI WOODS, JAMES H · 2016 to 2018
$1.7M
NIMH NIH HHS R01 MH107499
6 · The paper itself

Abstract

Despite the evidence that the muscarinic agonist arecoline is a drug of abuse throughout Southeast Asia, its stimulus characteristics have not been well studied. The goal of this work was to understand more about the mediation of discriminative stimulus effects of arecoline. Arecoline (1.0 mg/kg s.c.) was trained as a discriminative stimulus in a group of eight rats. The ability of various cholinergic agonists and antagonists to mimic or antagonize the discriminative stimulus effects of arecoline and to modify its rate-suppressing effects was evaluated. A muscarinic antagonist, but neither of two nicotinic antagonists, was able to modify the discriminative stimulus effects of arecoline, suggesting a predominant muscarinic basis of arecoline's discriminative stimulus effects in this assay. However, both nicotine itself and two nicotine agonists with selective affinity for the α4β2* receptor (ispronicline and metanicotine) produced full arecoline-like discriminative stimulus effects in these rats. The discriminative stimulus effects of the selective nicotine agonists were blocked by both the general nicotine antagonist mecamylamine and by the selective α4β2* antagonist, dihydro-beta-erythroidine (DHβE). Surprisingly, only DHβE antagonized the rate-suppressing effects of the selective nicotine agonists. These data indicate a selective α4β2* nicotine receptor component to the behavioral effects of arecoline. Although the nicotinic aspects of arecoline's behavior effects could suggest that abuse of arecoline-containing material (e.g. betel nut chewing) is mediated through nicotinic rather than muscarinic actions, further research, specifically on the reinforcing effects of arecoline, is necessary before this conclusion can be supported.

Indexed as

Substance-Related DisordersAnimalsArecolineBehavior, AnimalDihydro-beta-ErythroidineDiscrimination LearningMecamylamineMuscarinic AgonistsNicotineNicotinic AgonistsNicotinic AntagonistsPyridinesRatsReceptors, NicotinicArecolineDihydro-beta-ErythroidineisproniclineMecamylaminemetanicotineMuscarinic AgonistsNicotineNicotinic AgonistsNicotinic Antagonistsnicotinic receptor alpha4beta2PyridinesReceptors, Nicotinic

Identifiers

PMID34417356
PMCPMC8446330
OpenAlexW3196144719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.